What is the recommended dose of Glycolax (polyethylene glycol 3350) for a 3-year-old child with moderate constipation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Glycolax (Polyethylene Glycol 3350) Dosing for a 3-Year-Old

For a 3-year-old child with moderate constipation, start with 0.4 g/kg per day of polyethylene glycol 3350 mixed in 4-8 ounces of liquid, which typically translates to approximately 5-7 grams daily for an average-sized 3-year-old (12-18 kg). 1

Evidence-Based Starting Dose

  • The optimal starting dose of 0.4 g/kg per day is supported by the highest quality pediatric trial, which demonstrated 74% treatment success (≥3 bowel movements per week) compared to 42% with placebo 1
  • This dose provides the best balance of efficacy and tolerability, with significantly improved stool consistency (p < 0.001) and reduced straining (p < 0.05) 1
  • The 0.4 g/kg dose had fewer side effects than higher doses (0.8 g/kg caused more abdominal pain and fecal incontinence) 1

Dose Titration Strategy

  • Adjust the dose every 3 days based on response, with the goal of achieving 1-2 soft, non-forced bowel movements daily 2
  • The effective maintenance dose typically ranges from 0.26 to 1.42 g/kg per day, with a mean of 0.78-0.84 g/kg per day across multiple studies 3, 2
  • If no bowel movement occurs after 3-4 days, add a bisacodyl suppository (10 mg) or glycerin suppository while continuing PEG 4

Administration Guidelines

  • Mix the powder in at least 4-8 ounces of liquid (water, juice, coffee, or tea) 4
  • Juices containing sorbitol provide synergistic osmotic effects 4
  • Insufficient liquid volume is a common cause of treatment failure 4
  • Ensure adequate daily fluid intake beyond just the mixing liquid, as PEG requires water to work osmotically 4

Expected Timeline and Monitoring

  • Stool frequency should increase significantly within the first 1-2 weeks of treatment 2
  • Continue maintenance dosing once bowel movements normalize rather than stopping abruptly 4
  • Treatment can be safely continued for 6+ months with sustained efficacy 2, 5

Safety Profile in Young Children

  • PEG 3350 is safe and effective in children as young as 0-18 months at a mean dose of 0.78 g/kg per day 3
  • Common side effects include transient diarrhea (which resolves with dose adjustment), abdominal distension, flatulence, and nausea 3, 1
  • Rule out fecal impaction before starting therapy, which may require manual disimpaction or enema first 4
  • Contraindicated in bowel obstruction or paralytic ileus 4

Common Clinical Pitfalls to Avoid

  • Not using adequate liquid volume significantly reduces efficacy 4
  • Assuming treatment failure without first optimizing dose and confirming compliance 4
  • Starting with too high a dose (0.8 g/kg) increases side effects without improving efficacy 1
  • Delaying rectal intervention beyond 3-4 days without a bowel movement increases risk of impaction 4

Adjunctive Measures

  • Address any underlying constipation with dietary modifications (increased fluids, fiber if adequate fluid intake) 6
  • Encourage regular toileting habits, especially after meals 6
  • For persistent constipation despite optimal PEG dosing, consider adding oral stimulant laxative (senna or bisacodyl) 4

References

Research

Polyethylene glycol for constipation in children younger than eighteen months old.

Journal of pediatric gastroenterology and nutrition, 2004

Guideline

Pediatric Dosing of MiraLAX (Polyethylene Glycol 3350)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Polyethylene glycol 3350 without electrolytes for treatment of childhood constipation.

Canadian family physician Medecin de famille canadien, 2009

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.